Episode 13: The Sustainability of Innovation: An Interview with Rachel King, CEO, BIO

In our 2023 podcasts, there have been a series of revelations about the complexity and unintended consequences related to drug access and affordability. This episode explores the essential underlying tension between the notion that affordability and access are deteriorating while science is advancing so rapidly. We interview Rachel King, CEO of Biotechnology Innovation Organization (BIO), to explore the priorities for the industry and how the challenges related to patient access and affordability could jeopardize innovation for patients today and in the future. Rachel King, CEO, BIO (Biotechnology Innovation Organization)  John Crowley, Executive Chairman, Amicus Therapeutics James Robinson PhD, MPH, Chair, Health Policy and Management Division, Berkeley School of Public Health The Inflation Reduction Act Orphan Drug Act Orphan Cures Act PBM (pharmacy benefit management) Medicare Part D Step Therapy Cystic Fibrosis Foundation Therapies mentioned in this episode: RNAi Antisense mRNA Monoclonal antibody Email us at [email protected] us on social media! We’re on X as @RX4BetterAccess, LinkedIn and YouTube.